Author

J. Schueler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:proteomics· 3 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

G. M. Siegers· 3 shared I. Dutta· 3 shared D. Dieters-Castator· 2 shared J. Liu· 2 shared L.-M. Postovit· 2 shared A. B. Bukhari· 1 shared A. Brumwell· 1 shared A. Koromilas· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. M. Siegers

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Proteomic Characterization of Intrahepatic Cholangiocarcinoma Identifies Distinct Subgroups and Proteins Associated with Time-To-Recurrence

T. Werner, K.-L. Budau, M. Cosenza Contreras, F. Hause, K. Kurowski, N. Pinter, J. Schueler, M. Werner, C. Sigel, L. Tang, P. Bronsert, O. Schilling

This study identifies two proteomic subgroups of intrahepatic cholangiocarcinoma with distinct time-to-recurrence rates and biological processes.

bioRxiv · Feb 28, 2024 · PreprintCancer Biology

PEGylated recombinant Aplysia punctata ink toxin depletes arginine and lysine and inhibits growth of tumor xenografts

A. Wolkersdorfer, B. Bergmann, J. Adelmann, M. Ebbinghaus, E. Guenther, M. Gutmann, L. Hahn, R. Hurwitz, R. Kraehmer, F. Leenders, T. Luehmann, J. Schueler, L. Schmidt, M. Teifel, L. Meinel, T. Rudel

This study shows that PEGylated APIT reduces tumor growth in xenograft models by depleting arginine and lysine through amino acid oxidation.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology

Docosahexaenoic acid significantly reduces tumor cell growth in preclinical models of ovarian cancer

O. Bilyk, B. Hamedi, I. Dutta, M. Newell, A. B. Bukhari, A. M. Gamper, R. C. McVea, J. Liu, J. Schueler, G. M. Siegers, C. J. Field, L.-M. Postovit

This study shows that docosahexaenoic acid (DHA) enhances the anti-cancer effects of carboplatin in ovarian cancer models, reducing tumor growth and improving survival.

bioRxiv · Nov 10, 2020Cancer Biology

ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy

I. Dutta, D. Dieters-Castator, J. W. Papatzimas, A. Medina, J. Schueler, D. J. Derksen, G. Lajoie, L. M. Postovit, G. M. Siegers

This study identifies ADAM protease inhibition as a strategy to overcome resistance of breast cancer stem-like cells to γδ T cell immunotherapy by blocking MICA shedding.

bioRxiv · Jul 17, 2020Immunology

Translational control of breast cancer plasticity

M. Jewer, L. Lee, G. Zhang, J. Liu, S. D. Findlay, K. M. Vincent, K. Tandoc, D. Dieters-Castator, D. F. Quail, I. Dutta, M. Coatham, Z. Xu, B.-J. Guan, M. Hatzoglou, A. Brumwell, , L.-M. Postovit

The paper identifies hypoxia and drug-induced translational activation of NANOG, SNAIL, and NODAL isoforms that drive breast cancer plasticity and stem-cell-like phenotypes, with potential therapeutic implications.

bioRxiv · Apr 2, 2019Cancer Biology